ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 529

Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators

Stephen Hall1, Tsutomu Takeuchi 2, Glen Thomson 3, Paul Emery 4, Bernard Combe 5, Andrea Everding 6, Karel Pavelka 7, Yanna Song 8, Tim Shaw 9, Alan Friedman 9, In-Ho Song 10 and Eduardo Mysler 11, 1Monash University and Emeritus Research, Melbourne, Australia, 2Keio University School of Medicine, Tokyo, Japan, 3CIADS Research, Winnipeg, Canada, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 5CHU Montpellier, Montpellier University, Montpellier, France, 6HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, 7Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 8AbbVie Inc., North Chicago, IL, USA, North Chicago, 9AbbVie Inc., North Chicago, 10AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 11Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis, treatment and remission

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Treatments Poster I: Novel Treatments

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Across all phase 3 studies, treatment with upadacitinib (UPA), a JAK1-selective inhibitor, was associated with significantly higher remission (REM) rates, compared to placebo (PBO) or active comparators in  RA patients (pts) who were methotrexate (MTX)-naive,  had inadequate response to conventional synthetic (csDMARD-IR)  or had inadequate response or intolerance to biologic DMARDs (bDMARD-IR). 

REM definitions are based on composite scores of various individual assessments of disease activity. To determine the response to UPA on REM and component assessments, we assessed the proportions of pts achieving REM using multiple REM definitions, and the improvement in their respective individual components, compared to PBO or active comparators, in 3 different RA pt populations spanning a range of RA pt populations.

Methods: Three phase 3 studies included pts who were MTX naïve (SELECT EARLY, n=945), MTX-IR (SELECT COMPARE, n=1629) and bDMARD-IR (SELECT BEYOND, n=498).  The proportion of pts achieving REM at Week (Wk) 12 by 4 definitions (DAS28-CRP< 2.6; CDAI ≤2.8; SDAI ≤3.3 and Boolean, defined as ≤1 for TJC, SJC, patient’s global assessment of disease activity [PtGA], and CRP ≤1 mg/L) were determined.  For each definition of REM, the mean change in each of the respective component scores was also assessed. Binary endpoints are based on Non-responder imputation (NRI), and continuous endpoints on mixed-effect model repeat measurement (MMRM).  Comparisons were made between UPA-treated groups vs respective control arms (MTX, adalimumab [ADA] or PBO).

Results: Pt demographics and disease characteristics have been previously reported. 1-3 At 12 wks, in EARLY and COMPARE, a significantly greater proportion of pts receiving UPA 15 mg or 30 mg QD achieved REM by all 4 definitions vs MTX, PBO or ADA (Table). In BEYOND, (a refractory population many of whom  had inadequate response to multiple bDMARDs),   a significantly greater proportion of pts receiving UPA 30mg achieved all REM definitions vs PBO within the first 12 wks, with significantly greater proportions receiving UPA 15mg achieving DAS28-CRP< 2.6 and Boolean REM (Table).  Rates of REM in BEYOND further increased through Wk 24 for both dose groups.1 Compared to respective control groups, pts receiving UPA 15 or 30 mg QD had significantly greater improvements in each REM disease component (except for PhGA vs ADA in COMPARE).  Significantly more pts receiving UPA also achieved the required cutoffs on the individual components of Boolean REM compared to respective controls.

Conclusion: Significantly greater proportions of pts receiving UPA 15 or 30mg achieved REM by multiple definitions at 12 wks compared to PBO, MTX or ADA.  All disease activity components of each REM definition were significantly improved in pts receiving UPA compared to MTX or PBO, and all Boolean components were significantly improved in pts receiving UPA 15mg compared to ADA.

References:
1. Genovese et al 2018;Lancet.18;31116-4
2. van Vollenhoven R et al. Arthritis Rheumatol. 2018;70 -supp10-
3. Fleischmann et al. Arthritis Rheumatol. 2018;70 -supp10-


Disclosure: S. Hall, AbbVie, 2, 5, BMS, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, UCB Pharma, 2, 5; T. Takeuchi, AbbVie, 2, 5, 8, AbbVie GK, 2, 9, Asahi Kasei, 2, Asahikasei, 2, Asahikasei Pharma Corp., 2, Astellas, 2, 8, 9, Astellas Pharma Inc, 2, Astellas Pharma, Inc., 2, 5, 8, 9, Astra Zeneca, 2, AstraZeneca, 8, AYUMI, 2, 9, AYUMI Pharmaceutical Corporation, 2, BMS, 2, 8, Boehringer-ingelheim, 9, Bristol–Myers K.K., 9, Bristol-Myers, 2, Bristol-Myers Squibb, 8, Chugai, 2, 8, 9, Chugai Pharmaceutical Co, Ltd., 2, Daiichi Sankyo, 2, 8, 9, Daiichi Sankyo Co., Ltd., 2, Eisai, 2, 5, 8, 9, Eisai Co., Ltd., 2, Eli Lilly, 2, 8, Eli Lilly Japan, 9, Gilead Sciences, Inc., 9, GlaxoSmithKline K.K, 9, GSK, 8, Janssen, 2, 8, Janssen Pharmaceutical K.K, 9, Mitsubishi Tanabe, 2, 9, Mitsubishi Tanabe Pharma Co., 2, Mitsubishi-Tanabe Pharma Corp, 2, 8, 9, Nippon Kayaku, 2, Nipponkayaku, 2, 9, Nipponkayaku Co.Ltd., 2, Novartis, 2, 8, Novartis Pharma K.K, 2, 9, Novartis Pharma K.K., 2, Pfizer, 2, 8, Pfizer Japan, 2, 9, Pfizer Japan Inc., 2, Sanofi, 8, Sanofi K.K, 9, Shionogi & Co., 2, Shionogi & Co., LTD., 2, Taiho, 2, 8, 9, Taisho, 9, Taisho Toyama, 2, 8, Takahashi Industrial and Economic Research Foundation, 2, Takeda, 2, 8, Takeda Pharmaceutical Co., Ltd., 2, Teijin, 2, 8, UCB, 8, 9, UCB Japan, 9; G. Thomson, AbbVie, 2, Amgen, 5; P. Emery, AbbVie, 2, 5, 9, BMS, 2, 5, Bristol-Myers Squibb, 2, 5, 9, Gilead, 5, Lilly, 2, 5, 9, MSD, 2, 5, 9, Novartis, 2, 5, 9, Pfizer, 2, 5, 9, Roche, 2, 5, 9, Samsung, 2, 5, 9, Samsung Bioepis Co., Ltd., 2, Sandoz, 2, 5, 9, UCB, 2, 5, 9; B. Combe, AbbVie, 5, BMS, 5, 8, Chugai, 5, 8, Eli Lilly, 5, Eli Lilly and Company, 5, 8, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, Lilly, 5, 8, MSD, 2, 5, 8, Novartis, 5, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche-Chugai, 5, 8, Sanofi, 5, UCB, 5, USD, 5; A. Everding, Amgen, 5, Eli Lilly, 5, Novartis, 5; K. Pavelka, AbbVie, 8, Abbvie, 5, 8, Amgen, 5, 8, BMS, 8, Egis, 5, 8, Lilly, 5, 8, MSD, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 8; Y. Song, AbbVie, 3, 4, Abbvie, 1, 4; T. Shaw, Abbvie, 1, 4, AbbVie, 3, 4; A. Friedman, AbbVie, 1, 3, Abbvie, 1, 4; I. Song, AbbVie, 3, 4; E. Mysler, AbbVie, 2, 5, 8, BMS, 2, 5, Bristol-Myers Squibb, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Lilly, 2, 5, Novartis, 2, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Sandoz, 2, 5.

To cite this abstract in AMA style:

Hall S, Takeuchi T, Thomson G, Emery P, Combe B, Everding A, Pavelka K, Song Y, Shaw T, Friedman A, Song I, Mysler E. Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/characterization-of-remission-in-patients-with-rheumatoid-arthritis-treated-with-upadacitinib-or-comparators/. Accessed June 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-remission-in-patients-with-rheumatoid-arthritis-treated-with-upadacitinib-or-comparators/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies